Breakdown | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 |
---|---|---|---|---|---|
Income Statement | |||||
Total Revenue | 1.83B | 1.62B | 1.43B | 1.32B | 1.07B |
Gross Profit | 249.12M | 221.39M | 165.72M | 191.80M | 105.94M |
EBITDA | 262.55M | 292.79M | 278.53M | 278.37M | 199.74M |
Net Income | 2.79M | 3.04M | 33.61M | 44.32M | -1.75M |
Balance Sheet | |||||
Total Assets | 3.29B | 2.69B | 2.43B | 2.06B | 1.79B |
Cash, Cash Equivalents and Short-Term Investments | 740.02M | 342.57M | 127.83M | 134.61M | 102.02M |
Total Debt | 1.73B | 1.49B | 1.51B | 1.40B | 1.18B |
Total Liabilities | 2.15B | 1.88B | 1.94B | 1.71B | 1.53B |
Stockholders Equity | 902.31M | 630.70M | 333.00M | 228.90M | 165.74M |
Cash Flow | |||||
Free Cash Flow | 1.29M | 44.26M | -103.00M | -71.20M | 108.32M |
Operating Cash Flow | 233.02M | 220.86M | 146.42M | 149.49M | 233.76M |
Investing Cash Flow | -233.07M | -201.47M | -246.95M | -221.51M | -126.24M |
Financing Cash Flow | 397.95M | 195.63M | 93.65M | 104.67M | -45.56M |
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
---|---|---|---|---|---|---|---|
72 Outperform | $4.21B | 1,704.59 | -3.65% | ― | 12.76% | -231.18% | |
67 Neutral | $684.04M | 10.66 | 21.57% | ― | 25.92% | ― | |
58 Neutral | $3.45B | 137.59 | 5.88% | ― | 2.78% | -54.72% | |
50 Neutral | AU$2.64B | 3.25 | -57.47% | 2.67% | 36.37% | 14.48% | |
46 Neutral | $5.37B | ― | -4584.47% | ― | 28.74% | 18.25% | |
42 Neutral | $625.22M | ― | -11.76% | ― | 9.70% | -30.94% | |
40 Underperform | $353.96M | ― | -13.84% | ― | 7.38% | 60.45% |
On July 17, 2025, RadNet, Inc. announced the completion of its acquisition of iCAD, Inc., a leader in AI-powered breast health solutions. This acquisition, through RadNet’s subsidiary DeepHealth, integrates iCAD’s technology and capabilities, enhancing DeepHealth’s suite of AI-powered breast cancer image interpretation and workflow solutions. The merger is expected to accelerate AI adoption and expand access to advanced breast cancer screening technologies globally, impacting over 10 million mammograms annually and improving cancer detection rates and workflow efficiency.
The most recent analyst rating on (RDNT) stock is a Buy with a $94.00 price target. To see the full list of analyst forecasts on Radnet stock, see the RDNT Stock Forecast page.
On June 11, 2025, RadNet, Inc. announced that it secured a $100 million incremental term loan from Barclays Bank PLC, which will be used for future acquisitions and general corporate purposes. This financial move is part of an amendment to their existing credit agreement, with the new loan maturing on April 18, 2031. The loan enhances RadNet’s capacity to pursue strategic growth opportunities, supporting its national imaging center network and technology platforms. Additionally, at the 2025 Annual Meeting of Stockholders held on June 10, 2025, RadNet’s stockholders elected seven directors and approved the appointment of Ernst & Young LLP as the company’s independent registered public accounting firm for the year ending December 31, 2025.
The most recent analyst rating on (RDNT) stock is a Buy with a $65.00 price target. To see the full list of analyst forecasts on Radnet stock, see the RDNT Stock Forecast page.